TELA Bio Inc Dossier - Source-backed chat

TELA Bio Inc

TELANASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.24

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.25Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $56.4M

Enterprise Value $85.4M

Shares Outstanding 45.1M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

TELA Bio is a high-growth, commercial-stage medical technology company disrupting the soft-tissue reconstruction market with its OviTex and OviTex PRS reinforced tissue matrices. By leveraging a unique embroidered design that combines biologic material (ovine rumen) with minimal polymer fibers, TELA Bio offers a highly effective, cost-efficient alternative to permanent synthetic meshes and expensive human acellular dermal matrices (ADMs). Despite near-term bottom-line pressures and product mix headwinds in the U.S., the company's strong international expansion (+41% YoY in Q1 2026), fully staffed sales force, and strategic board refreshment position it well to accelerate adoption and achieve operating leverage.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$1.00

Mean target$2.10

High · most bullish analyst$3.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.0015%

U.S. product mix headwinds worsen, with smaller, lower-priced units dominating sales and severely depressing average selling prices. Hospital procurement departments push back on pricing, and adoption of robotic/laparoscopic configurations stalls. Cash burn accelerates, forcing highly dilutive equity financing or restrictive debt covenants.

Base CaseCentral scenario

$2.2560%

TELA Bio executes on its reiterated 2026 guidance of at least 8% revenue growth over 2025, supported by steady OviTex unit volume growth and international traction. U.S. product mix headwinds stabilize as sales reps successfully cross-sell larger configurations. Gross margins remain stable in the mid-to-high 60s, and the company gradually narrows its operating losses.

Bull CaseUpside scenario

$3.2525%

Rapid adoption of the newly launched OviTex LTR portfolio and larger-sized OviTex PRS configurations drives U.S. revenue growth back above 15%. International sales continue their hyper-growth trajectory, particularly in the UK NHS system. Operating expenses remain flat, allowing the company to reach cash-flow breakeven ahead of schedule by late 2027.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated technology combining natural tissue remodeling with synthetic strength, backed by strong clinical data (e.g., BRAVO study showing low recurrence rates).
Significant cost advantage over traditional biologic matrices, aligning with hospital value-based procurement initiatives.
Strong international momentum, highlighted by a 41% year-over-year increase in international sales in Q1 2026.
Refinanced debt facility with Perceptive Advisors providing up to $70 million in capital to support the path to profitability.

Key Investment Risks

Product mix headwinds in the U.S. where rapid growth of smaller-sized units offsets unit volume gains.
Persistent net losses and cash burn, with a net loss of $12.3 million in Q1 2026.
High concentration of manufacturing and supply through a single partner, Aroa Biosurgery.
Intense competition from established medtech giants with significantly greater commercial resources.

Thesis Invalidation Triggers

Full-year 2026 revenue growth falling below the guided 8% threshold.
Gross margin deteriorating below 60% due to persistent inventory write-offs or pricing pressure.
Failure to secure key hospital contract wins or loss of major group purchasing organization (GPO) access.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.